Header Logo

Connection

Michael Silverberg to Neoplasms

Back to Details
This is a "connection" page, showing publications Michael Silverberg has written about Neoplasms.
Michael Silverberg
Connection Strength
4.113
Neoplasms
  1. Timing of Antiretroviral Therapy Initiation and Risk of Cancer Among Persons Living With Human Immunodeficiency Virus. Clin Infect Dis. 2021 06 01; 72(11):1900-1909.
    View in: PubMed
    Score: 0.548
  2. Cumulative Incidence of Cancer Among Persons With HIV in North America: A Cohort Study. Ann Intern Med. 2015 Oct 06; 163(7):507-18.
    View in: PubMed
    Score: 0.370
  3. Survival among HIV-infected and HIV-uninfected individuals with common non-AIDS-defining cancers. Cancer Epidemiol Biomarkers Prev. 2015 Aug; 24(8):1167-73.
    View in: PubMed
    Score: 0.355
  4. Factors contributing to risk for cancer among HIV-infected individuals, and evidence that earlier combination antiretroviral therapy will alter this risk. Curr Opin HIV AIDS. 2014 Jan; 9(1):34-40.
    View in: PubMed
    Score: 0.328
  5. Exposure to antiretroviral therapy and risk of cancer in HIV-infected persons. AIDS. 2012 Nov 13; 26(17):2223-31.
    View in: PubMed
    Score: 0.303
  6. HIV infection, immunodeficiency, viral replication, and the risk of cancer. Cancer Epidemiol Biomarkers Prev. 2011 Dec; 20(12):2551-9.
    View in: PubMed
    Score: 0.283
  7. New insights into the role of HIV infection on cancer risk. Lancet Oncol. 2009 Dec; 10(12):1133-4.
    View in: PubMed
    Score: 0.247
  8. HIV infection and the risk of cancers with and without a known infectious cause. AIDS. 2009 Nov 13; 23(17):2337-45.
    View in: PubMed
    Score: 0.246
  9. Do antiretrovirals reduce the risk of non-AIDS-defining malignancies? Curr Opin HIV AIDS. 2009 Jan; 4(1):42-51.
    View in: PubMed
    Score: 0.232
  10. Risk of cancers during interrupted antiretroviral therapy in the SMART study. AIDS. 2007 Sep 12; 21(14):1957-63.
    View in: PubMed
    Score: 0.212
  11. AIDS-defining and non-AIDS-defining malignancies: cancer occurrence in the antiretroviral therapy era. Curr Opin Oncol. 2007 Sep; 19(5):446-51.
    View in: PubMed
    Score: 0.211
  12. The forecasted prevalence of comorbidities and multimorbidity in people with HIV in the United States through the year 2030: A modeling study. PLoS Med. 2024 Jan; 21(1):e1004325.
    View in: PubMed
    Score: 0.164
  13. Cancer-Attributable Mortality Among People With Treated Human Immunodeficiency Virus Infection in North America. Clin Infect Dis. 2017 Aug 15; 65(4):636-643.
    View in: PubMed
    Score: 0.105
  14. HIV Infection, Immunosuppression, and Age at Diagnosis of Non-AIDS-Defining Cancers. Clin Infect Dis. 2017 02 15; 64(4):468-475.
    View in: PubMed
    Score: 0.102
  15. Prevalence of non-HIV cancer risk factors in persons living with HIV/AIDS: a meta-analysis. AIDS. 2016 Jan; 30(2):273-91.
    View in: PubMed
    Score: 0.094
  16. Predicting risk of cancer during HIV infection: the role of inflammatory and coagulation biomarkers. AIDS. 2013 Jun 01; 27(9):1433-41.
    View in: PubMed
    Score: 0.079
  17. The epidemiology of herpes zoster in patients with newly diagnosed cancer. Cancer Epidemiol Biomarkers Prev. 2013 Jan; 22(1):82-90.
    View in: PubMed
    Score: 0.076
  18. HIV infection, aging, and immune function: implications for cancer risk and prevention. Curr Opin Oncol. 2012 Sep; 24(5):506-16.
    View in: PubMed
    Score: 0.075
  19. Cancer screening in patients infected with HIV. Curr HIV/AIDS Rep. 2011 Sep; 8(3):142-52.
    View in: PubMed
    Score: 0.070
  20. CD4+ count and risk of non-AIDS diseases following initial treatment for HIV infection. AIDS. 2008 Apr 23; 22(7):841-8.
    View in: PubMed
    Score: 0.014

© 2024 Kaiser Permanente